You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
復星醫藥(02196.HK)附屬擬732萬美元收購NOVA 49%權益
格隆匯 06-09 21:03

格隆匯6月9日丨復星醫藥(02196.HK)公吿,於2021年6月9日,買方Fosun Pharma USA Inc(公司附屬公司)與賣方Fosun Healthcare US LLC訂立收購協議,根據該協議賣方同意出售且買方同意以732 萬美元的收購價格購買賣方所持49%NOVA權益。於收購協議項下交易完成後,NOVA將會成為公司的全資附屬公司。

NOVA為一間於美國註冊成立的公司,其主要通過其附屬公司Novelstar從事有競爭力的仿製藥及改良劑型新藥項目的研發。截至公吿日期,買方及賣方於NOVA已累積投入的資金分別為約674萬美元及約647萬美元。

基 於NOVA的主營業務,公司擬通過訂立收購協議將持有NOVA的股權比例由51%增加至100%。於收購協議完成後,NOVA將成為公司的全資附屬公司。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account